Ann: First patient treated in theranostic prostate cancer trial, page-11

TLX-591CDx is a kit form of the already available (and fda approved) ga68-psma-11 compound.

CU6 SAR technology aims to be a more robust chelator for Cu64 opening new imaging options for neuroendocrine and prostate cancers and allowing for Pre-therapy dosimetry. I think this therefore has more risk and upside and yes we are very early on.

one thing not really mentioned is that cu64 would allow for much easier scheduling and workflow.

atm ga68 DOTATATE/PSMA-11 needs to be injected, patient waits around for an hr then gets scanned. any longee and the radioactivity decays significantly. with cu64 patient can get injected, go home and then come back the next day at any time. Better workflow efficiency (and scan throughput is a consideration for imaging practices).